Opus Genetics, Inc. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Form 8-K filed 2026-10-21 reports Item 5.02 events (departure of directors/officers and compensatory arrangements) effective 2026-10-19. Specific names, titles, dollar amounts, equity grants, dates of departure, and replacement officer details are not disclosed in the filing metadata provided—only the item codes are listed without substantive narrative content.
Why this rating
Routine officer/director disclosure with no quantified impact disclosed; cannot assess materiality without specific compensation or operational detail relative to $45.9M market cap.
Extracted items
- 5.02 exec change
- 9.01 exhibits
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.